Research programme: memory-enhancing therapies - Axonyx/Thomas Jefferson University
Latest Information Update: 08 Apr 2005
At a glance
- Originator Thomas Jefferson University
- Developer Thomas Jefferson University; TorreyPines Therapeutics Inc
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Learning disorders
Most Recent Events
- 08 Apr 2005 Discontinued - Preclinical for Learning disorders in USA (unspecified route)
- 20 Apr 2001 Preclinical development for Learning disorders in USA (unspecified route)